This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
This market research report includes a detailed segmentation of the global chronic kidney disease drugs market by drug class (antihypertensives, antihyperlipidemics, erythropoiesis-stimulating agents (ESAs), diuretics, and others), by end-users (hospitals and specialty clinics), by regions (North America, Europe, Asia Pacific, and Rest of the World).
The authors market research report predicts that the “Global Chronic Kidney Disease Drugs Market” will grow at a CAGR of 4.1% during the forecast period. The market has witnessed flat growth in the past few years and is sustaining only due to the steady rise in the incidence of renal disorders leading to chronic kidney disease, increasing incidences of cardiovascular and metabolism-related disorders, and growing geriatric population globally.
The growing market trend continues and is one of the increasingly accepted markets in many countries worldwide. Chronic kidney disease drugs manufacturers are focusing on obtaining funds and collaborating with universities to enlarge their R&D capabilities. A majority of the revenue is generated from the leading players in the market with dominant sales from AbbVie, Amgen, GlaxoSmithKline, Roche, and AstraZeneca.
According to the author's analysis, North America accounted for the largest share of the global chronic kidney disease drugs market in 2018. The US dominates the market owing to the presence of a majority of the chronic kidney disease drugs manufacturers in the region. However, the fastest growth rate is anticipated to be in the APAC region due to the large kidney disease patient population and increasing awareness about the disease.
By Drug Class:
- Erythropoiesis-stimulating agents (ESAs)
The antihypertensives segment occupied the largest share in 2018. Currently, KBP Biosciences and Medpace, Inc. are conducting Phase 2 randomized clinical trial on KBP-5074 for patients with moderate-to-severe chronic kidney disease and uncontrolled hypertension.
- Speciality Clinics
In 2018, hospitals accounted for the maximum share, followed by speciality clinics, due to the availability of technologically-advanced diagnostic equipment for the early diagnosis of the condition.
- North America
North America is dominant in the global chronic kidney disease drugs market, followed by Asia Pacific and Europe. The significant share of the North America market comes from the US due to the availability of good reimbursement policies.
Chronic Kidney Disease Drugs Market Research Competitive Analysis – The market is growing at a flat rate, with a single-digit CAGR during the forecast period. Various initiatives are taken by government establishments and market players to increase awareness among individuals. Campaigns are conducted globally to encourage people in adopting healthy lifestyles. Many countries are focusing on national programs to create disease awareness, prevention, and treatment options; for example, country-level national dialysis program, kidney disease education portals, the launch of kidney-related disorder treatment funding initiatives, etc. Exhaustive pipeline for chronic kidney disease drugs is promising and is much required for future market growth. For example, ROXADUSTAT (HIF-PHI) by FibroGen is currently being studied in Phase-III clinical trials in the US, Europe, China, and Japan. Dapagliflozin by AstraZeneca is currently in phase III to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease (Dapa-CKD).
- AbbVie Inc.
- Amgen Inc.
- GlaxoSmithKline Plc
- F. Hoffmann-La Roche Ltd.
Key Competitive Facts
Increasing CKD incidence, ageing population, promising repayment or reimbursement plans in few nations, and enormous R&D activities for the CKD drug development are the major factors driving the market growth.
Cell therapy produces better results in the earlier stages of kidney disease and has been shown to eliminate or reduce the need for regular dialysis.
Research is being conducted to study the potential of miRNA as effective biomarkers and therapeutic targets for CKD treatments.
The report provides complete details about the sub-segments of the chronic kidney diseases drugs market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward the disease management in the upcoming years along with details of the existing pureplay companies and new players entering the market. Moreover, the report provides details about the major challenges that are going to impact market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
- Understanding the potential market opportunity with precise market size and forecast data.
- A detailed market analysis focusing on the growth of chronic kidney diseases drugs industry.
- Factors influencing the growth of the chronic kidney disease drugs market.
- In-depth competitive analysis of dominant and pure-play vendors.
- Prediction analysis of the chronic kidney diseases drugs market in both developed and developing regions.
- Key insights related to major segments of the chronic kidney diseases drugs market.
- Latest market trend analysis impacting the buying behaviour of the consumers.
Table of Contents
1.2 Total Addressable Market
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3.2 Segmented Addressable Market (SAM)
3.3 Industry Trends
3.4 Related Markets
3.4.1 Active pharmaceutical ingredients (APIs)
3.4.2 Over-the-counter drugs (OTC)
3.4.3 Human Insulin
4.2 Porter 5 (Five) Forces
184.108.40.206 High incidence of chronic kidney disease (CKD)
220.127.116.11 Rise in incidence of cardiovascular disorders and diabetes
18.104.22.168 Increase in global geriatric population
22.214.171.124 Competition from biosimilars
126.96.36.199 Complex drug development process
188.8.131.52 Promising Drug Pipeline Chronic Kidney Disease
184.108.40.206 Market expansion opportunities in emerging nations
220.127.116.11 Novel therapeutic approaches such as cell therapy
5.1.4 DRO – Impact Analysis
5.2 Key Stakeholders
6.2 Erythropoiesis-stimulating agents (ESAs)
6.3 Diuretics Drugs
7.3 Specialty Clinic
8.2 North America
8.4 Asia Pacific
8.5 Rest of the World
10.1.2 Geographic Presence
10.1.3 Business Focus
10.1.4 SWOT Analysis
10.1.5 Business Strategies
10.2 Amgen Inc.
10.2.2 Geographic Presence
10.2.3 Business Focus
10.2.4 SWOT Analysis
10.2.5 Business Strategies
10.3 GlaxoSmithKline plc
10.3.2 Geographic Presence
10.3.3 Business Focus
10.3.4 SWOT Analysis
10.3.5 Business Strategies
10.4 F. Hoffmann-La Roche Ltd.
10.4.2 Business Units
10.4.3 Geographic Revenue
10.4.4 Business Focus
10.4.5 SWOT Analysis
10.4.6 Business Strategies
10.5 Astra Zeneca PLC
10.5.2 Geographic Presence
10.5.3 Business Focus
10.5.4 SWOT Analysis
10.5.5 Business Strategies
11.3 Teva Pharmaceutical Industries Ltd.
11.4 Johnson & Johnson
11.5 Keryx Biopharmaceuticals Inc
11.6 FibroGen Inc.
Table 2 Chronic Kidney Disease Drugs Market Revenue, By Drug Class, 2018-2025 ($Million)
Table 3 Chronic Kidney Disease Drugs Market Revenue, By Product Type, 2018-2025 ($Million)
Table 4 Abbvie Inc.: Offerings
Table 5 Abbvie Inc.: Recent Developments
Table 6 Amgen Inc.: Offerings
Table 7 Amgen Inc.: Recent Developments
Table 8 GlaxoSmithKline Plc: Offerings
Table 9 GlaxoSmithKline Plc: Recent Developments
Table 10 F. Hoffmann-La Roche Ltd.: Product Offerings
Table 11 F. Hoffmann-La Roche Ltd.: Recent Developments
Table 12 AstraZeneca Plc: Offerings
Table 13 AstraZeneca Plc: Recent Developments
Table 14 Pfizer Inc.: Snapshot
Table 15 Merck KGAA: Recent Developments
Table 16 Sanofi: Snapshot
Table 17 Sanofi: Recent Developments
Table 18 Teva Pharmaceutical Industries.: Overview
Table 19 Teva Pharmaceutical Indu tries: Recent Developments
Table 20 Editas Medicine: Overview
Table 21 Editas Medicine.: Recent Developments
Table 22 Keryx Biopharmaceuticals, Inc: Snapshot
Table 23 Keryx Biopharmaceuticals, Inc: Recent Developments
Table 24 Fibrogen Inc.: Overview
Table 25 Fibrogen Inc.: Recent Developments
Chart 2 Stages Of Chronic Kidney Disease
Chart 3 Chronic Kidney Disease Drugs Market Revenue, 2018-2025 ($Million)
Chart 4 Chronic Kidney Disease Drugs Market Segmentation
Chart 5 Porters 5 Forces On Chronic Kidney Disease Drugs Market
Chart 7 Market Dynamics – Drivers, Restraints & Opportunities
Chart 8 World Population Aged 65 Years And Above, 1960–2060 (%)
Chart 9 DRO - Impact Analysis Of Chronic Kidney Diseases Drugs Market
Chart 10 Key Stakeholders Of Chronic Kidney Disease Drugs Market
Chart 11 Chronic Kidney Diseases Drugs Market Segment Revenue By Drug Class, 2018 vs 2025 ($ Million)
Chart 12 Anti-Hypertensive Drugs Market Revenue, By Drug Class 2018-2025 ($Million)
Chart 13 Anti-Hyperlipidemic Drugs Market Revenue, By Drug Class 2018-2025 ($Million)
Chart 14 Erythropoiesis-Stimulating Agents (ESAS) Market Revenue, By Drug Class 2018-2025 ($Million)
Chart 15 Chronic Kidney Disease Drugs Market Revenue, By Drug Class 2018-2025 ($Million)
Chart 16 Other Chronic Kidney Disease Drugs Market Revenue, By Drug Class 2018-2025 ($Million)
Chart 17 Global Chronic Kidney Disease Drugs Market Segment Revenue, By End Users, 2018 (%)
Chart 18 Chronic Kidney Disease Drugs Market By Regional Segmentation, 2018 vs 2025 ($Million)
Chart 19 Chronic Kidney Disease Drugs Market Revenue In North America, 2018-2025 ($Million)
Chart 20 Chronic Kidney Disease Drugs Market Revenue In Europe, 2018-2025 ($Million)
Chart 21 Chronic Kidney Disease Drugs Market Revenue In Asia Pacific, 2018-2025 ($Million)
Chart 22 Chronic Kidney Disease Drugs Revenue In Rest Of The World, 2018-2025 ($Million)
Chart 23 Abbvie Inc.: Overview Snapshot
Chart 24 Abbvie Inc.: Geographic Presence
Chart 25 Abbvie Inc.: SWOT Analysis
Chart 26 Amgen Inc.: Overview Snapshot
Chart 27 Amgen Inc.: Geographic Presence
Chart 28 Amgen Inc.: SWOT Analysis
Chart 29 GlaxoSmithKline Plc: Overview Snapshot
Chart 30 GlaxoSmithKline Plc: Business Units
Chart 31 GlaxoSmithKline Plc: Geographic Presence
Chart 32 GlaxoSmithKline Plc: SWOT Analysis
Chart 33 F. Hoffmann-La Roche Ltd.: Overview Snapshot
Chart 34 F. Hoffmann-La Roche Ltd.: Business Units
Chart 35 F. Hoffmann-La Roche Ltd.: Geographic Revenue
Chart 36 F. Hoffmann-La Roche Ltd.: SWOT Analysis
Chart 37 AstraZeneca Plc: Overview Snapshot
Chart 38 Astra Zeneca Plc: Business Units
Chart 39 AstraZeneca Plc: Geographic Presence
Chart 40 Astra Zeneca Plc: SWOT Analysis
- AbbVie Inc.
- Amgen Inc.
- F. Hoffmann-La Roche Ltd.
- FibroGen Inc.
- GlaxoSmithKline Plc
- Johnson & Johnson
- KBP Biosciences
- Keryx Biopharmaceuticals Inc
- Medpace, Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.